Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) is a genomic medicine company whose news flow centers on clinical data, regulatory interactions, collaborations and financial updates across its neurology‑focused pipeline. Company announcements emphasize investigational programs in Fabry disease, chronic neuropathic pain and prion disease, along with progress in its zinc finger epigenetic regulation and AAV capsid platforms.
A major theme in recent SGMO news is the development of isaralgagene civaparvovec (ST‑920), a wholly owned investigational gene therapy for adults with Fabry disease. Press releases detail topline and updated results from the registrational Phase 1/2 STAAR study, including positive mean annualized estimated glomerular filtration rate (eGFR) slopes at 52 and 104 weeks, stability of cardiac endpoints, biomarker trends and quality‑of‑life measures. Regulatory milestones, such as FDA agreement to use eGFR slope as an endpoint for an accelerated approval pathway and acceptance of a rolling Biologics License Application (BLA) submission, are also key subjects.
Investors following SGMO news can also track developments in the Phase 1/2 STAND study of ST‑503 for intractable pain due to small fiber neuropathy, including FDA Fast Track Designation, site activation and recruitment updates. Additional releases describe preclinical and regulatory progress for ST‑506 in prion disease, as well as business development activities like the capsid license agreement with Eli Lilly and Company and other collaboration‑related revenues.
Quarterly earnings releases and conference call announcements provide context on Sangamo’s operating expenses, cash position and strategic focus on a neurology‑oriented genomic medicine business. For readers interested in SGMO, this news page aggregates these clinical, regulatory, partnership and financial disclosures in one place, making it easier to follow the company’s reported milestones over time.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) will participate in the virtual Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease conference on April 1, 2021. The management is set to join a panel discussion at 10 a.m. Eastern Time. The event will be webcast live and can be accessed via Sangamo's website. This engagement highlights Sangamo's commitment to advancing genomic medicines through gene therapy, cell therapy, and genome engineering, aimed at transforming patients' lives.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced that the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) has granted Orphan Designation for BIVV003, a gene-edited cell therapy for sickle cell disease, based on preliminary data from three patients with varying follow-up periods. The Committee noted potential long-term benefits that may reduce treatment frequency. Sangamo and Sanofi plan to present updated data from the ongoing PRECIZN-1 study at a medical meeting later this year, along with updates on ST-400 in beta thalassemia.
Sangamo Therapeutics reported a consolidated net loss of $40.7 million for Q4 2020, compared to a net income of $4.5 million in Q4 2019. Revenues dropped to $25.8 million from $54.9 million year-over-year. For the full year, the company posted a net loss of $121.1 million, versus $95.4 million in 2019, although total revenues rose to $118.2 million from $102.4 million due to new collaborations. Sangamo has expanded its AAV manufacturing capabilities and entered significant collaborations with Biogen and Novartis, focusing on expanding clinical operations in 2021.
Sangamo Therapeutics (Nasdaq: SGMO) has announced its participation in several upcoming investor conferences. Key events include the Cowen 41st Annual Health Care Conference on March 1 at 2:40 p.m. ET, the H.C. Wainwright Global Life Sciences Conference on March 9 at 7:00 a.m. ET, and the Barclays Global Healthcare Conference on March 10 at 10:55 a.m. ET. Live webcasts will be available on the company’s website under the Investors and Media section. Sangamo is focused on developing genomic medicines through innovative therapies.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) has announced the release of its fourth quarter and full year 2020 financial results, scheduled for February 24, 2021, after market close. A conference call will follow at 5:00 p.m. ET, where the company aims to review financial results and provide business updates. Participants can join via telephone or webcast. The call can be accessed using specific dial-in numbers for domestic and international callers, and a replay will be available for one week post-call.
Sangamo Therapeutics (Nasdaq: SGMO) has appointed Rob Schott, MD, MPH, FACC, as Senior Vice President and Head of Development. Dr. Schott will oversee clinical strategy and drive the company's late-stage pipeline. He previously served as Chief Medical Officer at Chorus, an Eli Lilly subsidiary. In addition, Jason Fontenot, PhD, has been promoted to Chief Scientific Officer, enhancing leadership amid ongoing clinical trials. This restructuring aims to improve the efficiency of translating scientific advancements into genomic medicines.
Sangamo Therapeutics (Nasdaq: SGMO) announced the departure of Chief Financial Officer Sung Lee, effective February 1, 2021, as he pursues an opportunity overseas. CEO Sandy Macrae praised Lee's significant contributions in strengthening the company's financial position, which supports its strategic initiatives in genomic medicine. The management team will begin the search for a new CFO. Lee expressed pride in his role at Sangamo, highlighting the company's readiness to execute its strategy.
Sangamo Therapeutics (Nasdaq: SGMO) will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 13th at 5:20 PM EST. The session will be available for live streaming on the company’s website in the Investors and Media section under Events and Presentations. Sangamo Therapeutics focuses on groundbreaking genomic medicine, utilizing gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing to transform patient lives.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced participation in two upcoming investor conferences. The 29th Annual Credit Suisse Virtual Healthcare Conference is on November 9 at 5 p.m. Eastern Time, and the Barclays Gene Editing & Gene Therapy Summit is scheduled for November 16 at 10:45 a.m. Eastern Time. Both presentations will be webcast live and later available on their website under the Investors and Media section. Sangamo focuses on advancing genomic medicines through gene therapy and genome editing.
Sangamo Therapeutics reported Q3 2020 financial results, showing revenues of $57.8 million, up from $22.0 million in Q3 2019. The company achieved a $30 million milestone from Pfizer for dosing the first patient in the Phase 3 AFFINE study for hemophilia A gene therapy. Cash and equivalents increased to $694.6 million. Despite a net loss of $1.6 million (or $0.01 per share), down from a loss of $27.3 million in the prior year, operating expenses rose to $61.5 million. The company revised its operating expense guidance for 2020 to $210 to $220 million.
FAQ
What is the current stock price of Sangamo Therapeutics (SGMO)?
What is the market cap of Sangamo Therapeutics (SGMO)?
